Over the last 7 days, the market has remained flat, while over the past 12 months, it has risen by 20%, with earnings forecast to grow by 18% annually. Investing in penny stocks—though a somewhat outdated term—can still open doors to growth opportunities, particularly in smaller or newer companies. These stocks can offer significant returns when backed by strong financial health; we'll explore several examples that combine balance sheet strength with potential for outsized gains.

Let's review some notable picks from our screened stocks.

Seer (SEER)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Seer, Inc. is a life sciences company focused on developing and commercializing products to decode the biology of the proteome for improved human health across various global markets, with a market cap of $89.07 million.

Operations: Seer's revenue primarily comes from its Biotechnology (Startups) segment, which generated $15.17 million.

Market Cap: $89.07M

Seer, Inc., with a market cap of US$89.07 million, operates in the life sciences sector and is currently unprofitable. Despite generating US$15.17 million from its Biotechnology segment, it faces challenges such as a volatile share price and increased losses over five years. The company is debt-free and has substantial short-term assets of US$181.6 million, covering its liabilities comfortably and providing a cash runway exceeding three years based on current free cash flow trends. Recent investor activism highlights governance concerns, with proposals for board changes amid ongoing strategic reviews following acquisition offers deemed undervalued by Seer's board.

Dingdong (Cayman) (DDL)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Dingdong (Cayman) Limited is an e-commerce company in China with a market cap of approximately $419 million.

Operations: The company's revenue primarily comes from its online retail operations, which generated approximately CN¥24.45 billion.

Market Cap: $419M

Dingdong (Cayman) Limited, with a market cap of approximately US$419 million, has demonstrated significant revenue growth, reporting CN¥139.39 million for Q1 2026 compared to CN¥47.22 million the previous year. Despite recent negative earnings growth and low return on equity at 14%, the company remains debt-free and has improved its financial health by eliminating past debt levels. Its short-term assets exceed liabilities, ensuring liquidity stability. The board and management team are experienced with average tenures above industry norms. Analysts anticipate a stock price increase of over 60%, although profit margins have declined recently from 1.4% to 0.7%.

ZKH Group (ZKH)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: ZKH Group Limited operates a trading and service platform for maintenance, repair, and operating (MRO) products, including spare parts and office supplies in China, with a market cap of approximately $344.85 million.

Operations: The company's revenue primarily comes from its business-to-business trading and services of industrial products, amounting to CN¥9.17 billion.

Market Cap: $344.85M

ZKH Group, with a market cap of approximately US$344.85 million, reported Q1 2026 revenue of CN¥2.11 billion, up from CN¥1.94 billion the previous year, while net losses narrowed significantly to CN¥10.1 million from CN¥66.72 million. Despite being unprofitable and having a negative return on equity (-2.86%), the company has reduced its losses by 43.9% annually over five years and maintains sufficient cash for over three years based on current free cash flow levels. ZKH's short-term assets exceed both short- and long-term liabilities, indicating solid liquidity despite an inexperienced board with an average tenure of 2.6 years.

Where To Now?

• Jump into our full catalog of 321 US Penny Stocks here.
• Seeking Other Investments? Explore 27 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.